

Susan Hanley, please

SEARCH REQUEST FORM

RECEIVED

S1741

Requestor's Name: Sabika Qazi SEP 2 Serial Number: 09/619, 493
 Date: 9/26/01 Phone: 303 (310) 3910 Art Unit: 1616

Search Topic:

Please write a detailed statement of search topic. Describe specifically as possible the subject matter to be searched. Define any terms that may have a special meaning. Give examples or relevant citations, authors keywords, etc., if known. For sequences, please attach a copy of the sequence. You may include a copy of the broadest and/or most relevant claim(s).

Please search for

Method of treating premenstrual dysphoric disorder (PMDD) by combination of gestagens and estrogens.

Selected species of gestagen is drospirenone and form of estrogen is ethynodiol dienoate.

Pl. see attached sheets.

thank you

Point of Contact:
 Susan Hanley
 Technical Info. Specialist
 CM1.12C14 Tel: 305-4053

9/22

STAFF USE ONLY

Date completed: 10/2
 Searcher: Hanley
 Terminal time: 10
 Elapsed time: _____
 CPU time: _____
 Total time: _____
 Number of Searches: _____
 Number of Databases: _____

Search Site	Vendors	
STIC	372	IG Suite
CM-1		STN
Pre-S		Dialog
Type of Search		APS
N.A. Sequence		Geninfo
A.A. Sequence		SDC
Structure		DARC/Questel
Bibliographic		Other

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Norman NASHED

Examiner: NOT YET ASSIGNED

Application of Parent

09/619,493

Serial No.: 09/331,397

Group Art Unit: NOT YET ASSIGNED

Filed: July 19, 2000

For: **THERAPEUTIC GESTAGENS FOR THE TREATMENT OF PREMENSTRUAL DYSPHORIC DISORDER**

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington, D. C. 20231

Sir:

Prior to examination, please amend the accompanying application as follows.

IN THE ABSTRACT:

Please delete the Abstract of the Disclosure in its entirety, and substitute therefor the Abstract which appears on a separate sheet attached hereto.

IN THE CLAIMS:

In the title, change "Claims" to --We claim:--

Please amend the claims as follows:

1. (Amended) [Use of a therapeutic gestagen for the production of a pharmaceutical agent for the treatment of] A method of treating premenstrual dysphoric disorder [(PMDD)], comprising administering to a patient in need of such treatment a therapeutically effective amount of gestagen.

2. (Amended) [Use of] The method of claim 1, wherein the gestagen is drospirenone, cyproterone acetate, or dienogest [according to claim 1].

3. (Amended) [Use according to] The method of claim 1, further comprising administering [together with] an estrogen.

4. (Amended) [Use according to] The method of claim 3, wherein the estrogen is
[together with a]synthetic [estrogen].

5. (Amended) [Use according to] The method of claim 4, [together with] wherein the
estrogen is ethinylestradiol.

6. (Amended) [Use according to] The method of claim 3, [together with] wherein the
estrogen is an estrogen sulfamate.

7. (Amended) [Use according to] The method of claim 3, [together with a] wherein the
estrogen is natural [estrogen].

8. (Amended) [Use according to] The method of claim 7, [together with] wherein the
estrogen is estradiol, estradiol valerate or another estradiol ester.

9. (Amended) [Use according to] The method of claim 1, wherein the gestagen is
administered only during the luteal phase of the female menstrual cycle.

10. (Amended) [Use according to] The method of claim 9, wherein the gestagen is
administered from day 10 to 28 of the menstrual cycle.

11. (Amended) [Use of] The method of claim 1, wherein the gestagen is [according to
claim 1] drospirenone, and it is administered in an amount of 0.5 mg to less than 5 mg daily.

12. (Amended) [Use of ethinylestradiol according to] The method of claim 5, wherein the
ethinylestradiol is administered in an amount of 0.010 to 0.05 mg daily.

13. (Amended) [Use of estradiol according to] The method of claim 8, wherein estradiol
is administered in an amount of 1.0 [g] to 3.0 mg daily.

Please add the following new claims:

--14. The method of claim 2, wherein the gestagen is drospirenone.

15. The method of claim 3, wherein the gestagen and estrogen are administered together.

16. The method of claim 15, wherein the gestagen and estrogen are administered orally.

A2

17. The method of claim 8, wherein the estrogen is estradiol.

18. The method of claim 11, wherein the daily dose of drospirenone is 1.0 to 4.0 mg.

19. The method of claim 4, wherein the estrogen is an estratrien-3-amidosulfonate.

20. The method of claim 4, wherein the estrogen is a 14a, 15a-methylene steroid from the estrane series.

21. The method of claim 3, wherein the gestagen and estrogen are administered continuously.

22. The method of claim 3, wherein the gestagen and estrogen are administered sequentially.

23. The method of claim 3, wherein the gestagen and estrogen are administered cyclically.--